NZ533417A - The method of treating cancer - Google Patents

The method of treating cancer

Info

Publication number
NZ533417A
NZ533417A NZ533417A NZ53341702A NZ533417A NZ 533417 A NZ533417 A NZ 533417A NZ 533417 A NZ533417 A NZ 533417A NZ 53341702 A NZ53341702 A NZ 53341702A NZ 533417 A NZ533417 A NZ 533417A
Authority
NZ
New Zealand
Prior art keywords
mycobacterium
pharmaceutical composition
cancer
constituents
effects
Prior art date
Application number
NZ533417A
Other languages
English (en)
Inventor
Bakulesh Mafatial Khamar
Original Assignee
Bakulesh Mafatial Khamar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bakulesh Mafatial Khamar filed Critical Bakulesh Mafatial Khamar
Publication of NZ533417A publication Critical patent/NZ533417A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ533417A 2001-12-10 2002-12-10 The method of treating cancer NZ533417A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1167MU2001 2001-12-10
PCT/IB2002/005516 WO2003049667A2 (en) 2001-12-10 2002-12-10 The method of treating cancer

Publications (1)

Publication Number Publication Date
NZ533417A true NZ533417A (en) 2008-04-30

Family

ID=11097334

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ533417A NZ533417A (en) 2001-12-10 2002-12-10 The method of treating cancer

Country Status (9)

Country Link
US (1) US7972609B2 (enExample)
JP (1) JP4527979B2 (enExample)
AP (1) AP1896A (enExample)
AU (1) AU2002348738B2 (enExample)
CA (1) CA2469266C (enExample)
GB (1) GB2389532C (enExample)
NZ (1) NZ533417A (enExample)
UA (1) UA79952C2 (enExample)
WO (1) WO2003049667A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1948782T3 (pl) 2005-04-25 2013-01-31 Cadila Pharmaceuticals Ltd Adiuwanty szczepionki
GB2464231B (en) * 2006-11-23 2010-08-04 Cadila Pharmaceuticals Ltd Poly-TLR antagonist
CA2681420A1 (en) * 2007-03-20 2008-09-25 Cadila Pharmaceuticals Limited P38 inhibitors
WO2009001204A2 (en) * 2007-06-28 2008-12-31 Cadila Pharmaceuticals Ltd. Mitogen activated protein kinase modulator
WO2011083493A1 (en) * 2010-01-08 2011-07-14 National Institute Of Immunology Human chorionic gonadotropin (hcg) based vaccine for prevention and treatment of cancer
US9795659B2 (en) * 2010-02-19 2017-10-24 Cadila Pharmaceuticals, Ltd. Pharmaceutical composition of killed cells with substantially retained immunogenicity
MX340143B (es) * 2010-10-13 2016-06-28 Telesta Therapeutics Ip Inc Composiciones de pared de célula de ácido ribonucléico bacterial y métodos para hacerlas y usarlas.
RU2580888C2 (ru) * 2011-01-11 2016-04-10 Кадила Фармасьютикалз Лимитед Фармацевтическая композиция для лечения рака
TR201101874A2 (tr) * 2011-02-25 2011-08-22 Leyla A�An Nac�Ye Yüzeyel mesane tümorü tedavisinde kullanılabilecek mycobacterıum(mikobakteri) brumae hücre duvarı ekstreleri.
WO2012117323A1 (en) * 2011-02-28 2012-09-07 Cadila Pharmaceuticals Limited Therapeutic cancer vaccine
JP2014521599A (ja) * 2011-07-05 2014-08-28 カディラ ファーマシューティカルズ リミテッド がん抗原
US20200368293A1 (en) * 2018-01-18 2020-11-26 Vedanta Biosciences, Inc. Compositions and methods for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
GB9223816D0 (en) * 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5767156A (en) * 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US5869645A (en) * 1997-10-15 1999-02-09 Board Of Trustees Of The University Of Illinois Method for isolating high molecular weight antineoplastic glycans using urea
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
WO2003075824A2 (en) * 2002-03-08 2003-09-18 Modi, Rajiv, Indravadan Process of manufacturing pharmaceutical composition useful for management of tuberculosis

Also Published As

Publication number Publication date
GB2389532B (en) 2004-10-27
JP2005528332A (ja) 2005-09-22
US20070259005A1 (en) 2007-11-08
WO2003049667A3 (en) 2003-10-09
GB0322773D0 (en) 2003-10-29
GB2389532C (en) 2005-09-08
CA2469266C (en) 2014-02-11
US7972609B2 (en) 2011-07-05
CA2469266A1 (en) 2003-06-19
AP2004003070A0 (en) 2004-06-30
AU2002348738B2 (en) 2007-11-08
GB2389532A (en) 2003-12-17
AP1896A (en) 2008-10-08
JP4527979B2 (ja) 2010-08-18
AU2002348738A1 (en) 2003-06-23
WO2003049667A2 (en) 2003-06-19
UA79952C2 (en) 2007-08-10

Similar Documents

Publication Publication Date Title
CA1333152C (en) Vaccine containing tumor antigens and adjuvants
US7972609B2 (en) Method of treating cancer
WO2003049751A1 (en) The process of manufacturing a pharmaceutical composition useful for management of cancer
CN107802831B (zh) 一种灭活乳酸菌疫苗佐剂
Zhu et al. Innovative applications of bacteria and their derivatives in targeted tumor therapy
JPH08508976A (ja) 改善化免疫療法用組成物
US20120014985A1 (en) Vaccine Adjuvants
US9056073B2 (en) Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
Divyashree et al. Bugs as drugs: neglected but a promising future therapeutic strategy in cancer
Steenken Jr et al. Vaccinating properties of avirulent dissociates of five different strains of tubercle bacilli
CN101518549A (zh) 分枝杆菌提取物的研究和应用
WO2010031883A1 (es) Agente inmunoterapéutico apropiado para la profilaxis primaria de la tuberculosis
Shahbaz et al. Current advances in microbial-based cancer therapies
US11213555B2 (en) Intravenous injection for enhancing immune function
EP0644773B1 (fr) Complexe immunomodulateur anti-sida
Julián et al. Bacteria-Derived Alternatives to Live Mycobacterium bovis Bacillus Calmette–Guerin for Nonmuscle Invasive Bladder Cancer Treatment
US6806253B2 (en) Immunodulatory complex and use thereof in helicobacter diseases
CN109078177B (zh) 一种预防结核病的疫苗及联合用药物和制备方法、应用
CN120082471A (zh) 一种中药益生菌组合物及其在增强免疫力和/或抗肺癌中的应用
CN120241808A (zh) 益生菌在制备与溶瘤病毒组合使用的抗肿瘤药物中的用途

Legal Events

Date Code Title Description
PSEA Patent sealed
S35A Application for proceedings under section 35 (restoration of lapsed patents)
RENW Renewal (renewal fees accepted)
S35R Proceedings under section 35 (restoration of lapsed patents): patent restored
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 DEC 2016 BY FRASER OLD + SOHN

Effective date: 20151208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 DEC 2017 BY FRASER OLD + SOHN

Effective date: 20161118

LAPS Patent lapsed